Polysaccharide and uses thereof
AssigneeGlaxosmithkline Biologicals SA
InventorsMichael T. Kowarik, Michael L. Wetter, Stefan J. Kemmler, Micha A. Häuptle, Veronica Gambillara, Manuela Mally
Life of this patent
Estimating the term…
Abstract
Provided herein is an E. coli O polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.
Claims20
A pharmaceutical composition comprising a glycoconjugate of an E. coli O25B antigen covalently coupled to a carrier protein, wherein the E. coli O25B antigen comprises the structure of Formula O25B′:
- wherein n is an integer of 1 to 30;
- and a pharmaceutically acceptable carrier.
A composition comprising a conjugate of an E. coli O25B polysaccharide antigen covalently coupled to an Asn residue in a carrier protein.
A method of producing a pharmaceutical composition comprising the step of combining:
- a) an E. coli O25B glycoconjugate comprising an O25B′ antigen covalently joined a carrier, wherein the O25B′ antigen has the structure:
- wherein n is an integer of 1 to 30;
- and
- b) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.